CAD & Atherosclerosis
Conference Coverage
Calcium scores predict sudden-death risk in preclinical CAD
The findings strengthen the case for initial CAC imaging as a gatekeeper to further testing in some primary-prevention patients, researchers say...
From the Journals
Even light drinking ups CV risk; harm rises along with intake
All levels of alcohol intake are harmful with regard to cardiovascular disease, and the risk increases exponentially as alcohol intake rises, even...
Conference Coverage
Hybrid ACC 2022 resurrects the live scientific session
The ACC offers a traditional in-person meeting spanning all of cardiology paired with what could be a lasting legacy of the pandemic, a robust,...
Conference Coverage
Coffee drinking may cut heart disease risk, prolong survival
A third analysis showed that the benefits of the same level of coffee drinking were observed whether the coffee consumed was instant or brewed...
From the Journals
Sit-to-stand BP spike tied to CV events in young adults
Orthostatic hypertension blood pressure assessment provides prognostic information on top of traditional risk factors and ambulatory blood...
Feature
Pfizer recalls BP drugs because of potential carcinogen
The voluntary nationwide recall of the antihypertensive Accuretic and two generics was prompted by unacceptable levels of N-nitroso-quinapril, a...
From the Journals
New test for Lp(a) allows more accurate LDL-cholesterol results
A new method of directly measuring Lp(a) has been shown to allow more accurate values for LDL cholesterol to be calculated in some patients.
Feature
Doctors treat osteoporosis with hormone therapy against guidelines
Some postmenopausal women may be appropriate candidates for the use of hormone therapy for the prevention of osteoporosis and fractures.
Guidelines
New ACC guidance on cardiovascular consequences of COVID-19
A new consensus document makes recommendations on how to evaluate and manage COVID-associated myocarditis and long COVID; it also gives advice on...
Latest News
Cancer increases patients’ risk for cardiovascular deaths
The extent of the risk varied somewhat by cancer stage, time from diagnosis, and cancer type.
Conference Coverage
Real-world data support safety of newer LAA device
More than 18 months after approval, the Watchman FLX left atrial appendage closure device is performing well at 45 days in real-world use.